Phaseline

Targets › IL15

IL15 (Interleukin-15): drug programs, companies and trials

17 programs from 12 companies in 23 trials: 19 Phase 1, 4 Phase 2; Oncology, Immunology; next expected readout Nov 2026.

Cytokine that plays a major role in the development of inflammatory and protective immune responses to microbial invaders and parasites by modulating immune cells of both the innate and adaptive immune systems. Stimulates the proliferation of natural killer cells, T-cells and B-cells and promotes the secretion of several cytokines. (UniProt, P40933)

Open in Phaseline: the race on IL15, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
SWOG Cancer Research NetworkNogapendekin Alfa (N-803, ALT-803)
IL-15/IL-15Rα fusion protein that activates natural killer cells
IL15, IL2RAPhase 2Advanced Lung Non-Small Cell CarcinomaJun 2027
The First Hospital of Jilin UniversityIL-15-armored BCMA-targeted CAR-T cells
IL-15-armored CAR-T cells targeting BCMA
TNFRSF17, IL15Phase 2Relapsed/Refractory Multiple MyelomaJul 2028
M.D. Anderson Cancer CenterNY-ESO-1 TCR/IL-15 NK
NY-ESO-1 T-cell receptor (TCR)-engineered natural killer cells with IL-15 co-expression
NY-ESO-1, IL15Phase 1Synovial SarcomaNov 2026
Second Affiliated Hospital, Zhejiang University, School of Medicineanti-CD19 IL10/IL15 CAR-NK
anti-CD19 chimeric antigen receptor NK cells engineered to co-express IL-10 and IL-15
CD19, IL10, IL15Phase 1B-cell Non Hodgkin LymphomaDec 2026
Suzhou Forlong BiotechnologyFL115
IL-15 agonist (IL-15[N72D]/IL-15Rα-sFc fusion protein)
IL15, IL15RAPhase 1Locally Advanced/Metastatic Solid Tumors; Advanced Solid Tumors; Non-muscle Invasive Bladder Cancer (NMIBC)Dec 2026
Beijing BiotechEB-DUO-CAR-NK-CEA/GCC
Dual-target CAR-NK cell therapy targeting CEA and GUCY2C (or CEA and HER2, or GUCY2C and H
CEACAM5, GUCY2C, ERBB2, CEA, HER2, IL15Phase 1Colorectal Cancer; Colorectal Cancer MetastaticMar 2027
Masonic Cancer Center, University of MinnesotaGTB-3650
Tri-specific killer engager (TriKE) targeting CD16 on NK cells, IL-15 co-stimulation, and
CD16, IL15, CD33Phase 1Myeloid MalignancyMar 2027
Bangdong GongiC9/CAR19/IL15 CB-NK cell
Chimeric Antigen Receptor Natural Killer Cell targeting CD19 with inducible suicide gene (
TNFRSF9, CD19, IL15Phase 1Primary Sjogren's SyndromeOct 2027
Innovent Biologics (Suzhou)IBI3013
Recombinant anti-IL-15 monoclonal antibody
IL15Phase 1HealthyDec 2027
M.D. Anderson Cancer CenterTROP2 CAR/IL-15 TGFBR2 KO NK cells
CAR-T cell therapy targeting TROP2 with IL-15 transduction and TGFBR2 knockout in cord blo
TROP2, IL15, TGFBR2Phase 1Head and Neck CancerDec 2027
M.D. Anderson Cancer CenterTGFBR2 KO CAR27/IL-15 NK cells
TGFBR2 knock-out cord blood-derived NK cells transduced with IL-15 and engineered with CAR
TGFBR2, IL15Phase 1Myeloid MalignanciesMay 2028
M.D. Anderson Cancer CenterTGFBR2 KO CAR27/IL-15 NK cells
TROP2-targeted CAR-NK cells with IL-15 co-expression and TGFBR2 knockout
TROP2, TGFBR2, IL15Phase 1Gastric Cancer, Metastatic; LymphoidJul 2028
M.D. Anderson Cancer CenterAllogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer
Cord blood-derived NK cells transduced with NY-ESO-1 T-cell receptor and IL-15
NY-ESO-1, IL15Phase 1Relapsed/Refractory MyelomaAug 2028
University of California, IrvineCOH06
Genetically engineered NK cells expressing PD-L1 and expressing/secreting IL-15
PDCD1LG2, IL15Phase 1Advanced Lung Non-Small Cell CarcinomaNov 2028
UNC Lineberger Comprehensive Cancer CenteriC9.GD2.CAR.IL-15 T-cells
CAR-T cells targeting GD2 with IL-15 co-expression and inducible caspase-9 safety switch
GD2, IL15Phase 1NeuroblastomaMay 2030
M.D. Anderson Cancer CenterCAR.5/IL15-transduced CB-NK cells
CD5-targeted CAR NK cells engineered with IL-15
CD5, IL15Phase 1Hematological MalignancyDec 2030
Instituto de Investigación Hospital Universitario La PazNK cells stimulated ex vivo with IL-15
Natural Killer cells stimulated ex vivo with IL-15 to enhance cytotoxic function
IL15Phase 1High-risk Leukemias–

Conditions

Relapsed/Refractory Multiple Myeloma (3) Advanced Lung Non-Small Cell Carcinoma (2) B-cell Non Hodgkin Lymphoma (1) Hematological Malignancy (1) Gastric Cancer, Metastatic (1) Lymphoid (1) Myeloid Malignancies (1) Colorectal Cancer (1) Colorectal Cancer Metastatic (1) Relapsed/Refractory Myeloma (1) Primary Sjogren's Syndrome (1) Neuroblastoma (1)

Modalities

mixed (8), small molecule (5), other (3), protein or peptide (1)

Companies

M.D. Anderson Cancer Center (6) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) The First Hospital of Jilin University (1) Beijing Biotech (1) Bangdong Gong (1) University of California, Irvine (1) UNC Lineberger Comprehensive Cancer Center (1) Masonic Cancer Center, University of Minnesota (1) Suzhou Forlong Biotechnology (1) SWOG Cancer Research Network (1) Instituto de Investigación Hospital Universitario La Paz (1) Innovent Biologics (Suzhou) (1)

Related targets

TGFBR2 (3) CD19 (2) TROP2 (2) NY-ESO-1 (2) IL10 (1) CD5 (1) TNFRSF17 (1) CEACAM5 (1) GUCY2C (1) ERBB2 (1) CEA (1) HER2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.